Investigation of The Effectiveness of Antioxidant Therapy in Oligoasthenoteratozoospermic Infertile Men
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT06042738 |
Recruitment Status :
Completed
First Posted : September 21, 2023
Last Update Posted : September 21, 2023
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Male Infertility | Combination Product: proxeed plus | Not Applicable |
Material and Method: The study included subfertile men with idiopathic oligoasthenoteratozospermia seen at Ondokuz Mayıs University Faculty of Medicine between March 2021 and November 2021.
All subjects were recommended to do moderate physical activity for at least 45 minutes (at least 150 minutes-600 METs per week) 3-4 days a week for three months. A total of 48 cases were divided into two groups by computer-assisted (www.randomizer.org) complete (simple) randomization. In the first group (Group 1), 2000 mg L-carnitine, 2000 mg fructose, 932 mg acetyl L-carnitine, 225 mg vitamin C, 115 mg citric acid, 50 mg coenzyme Q10, 14 mg zinc, 115 µg selenium, 3750 µg Food supplement containing vitamin B12 and 500 µg folic acid was recommended as one sachet in the morning and evening, while antioxidant food supplement was not given to the second group (group 2). Before and after treatment, semen parameters, Hormone analyzes with ELISA method, physical activity evaluation with IPAQ questionnaire, seminal antioxidant capacity with Trolox equivalent antioxidant capacity (TEAC) measurement method, DNA fragmentation index with TUNEL method. and sperm chromatin structure was evaluated by aniline blue staining.
Student's t test was used for the variables showing normal distribution in independent groups, and Mann Whitney U test was used for the variables that did not fit the normal distribution. Paired t test was used for the variables showing normal distribution in the dependent groups, and Wilcoxon test was used for the variables that were found not to fit the normal distribution.
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 48 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Intervention Model Description: | two groups with full (simple) randomization |
Masking: | Double (Participant, Investigator) |
Primary Purpose: | Supportive Care |
Official Title: | The Impact of Antioxidant Food Supplementation on Seminal Antioxidant Capacity, Sperm DNA Fragmentation and Sperm Chromatin Quality in Subfertile Men With Oligoastenoteratozoospermia Randomized Clinical Trial |
Actual Study Start Date : | March 1, 2021 |
Actual Primary Completion Date : | November 1, 2021 |
Actual Study Completion Date : | November 1, 2021 |
Arm | Intervention/treatment |
---|---|
Active Comparator: Group 1
group receiving antioxidant support
|
Combination Product: proxeed plus
Group 1 was recommended to receive a food supplement containing 2000 mg L-carnitine, 2000 mg fructose, 932 mg acetyl L-carnitine, 225 mg vitamin C, 115 mg citric acid, 50 mg coenzyme Q10, 14 mg zinc, 115 µg selenium, 3750 µg vitamin B12 and 500 µg folic acid as one sachet in the morning and evening |
No Intervention: Group 2
group that did not receive antioxidant support
|
- Total Antioxidant Capacity [ Time Frame: 3 months ]
Total Antioxidant Capacity (TAC) was measured by the colorimetric assay using the antioxidant Assay Kit (Cayman Chemical, Michigan, USA). All seminal plasma samples were diluted prior to analysis. Standards were diluted sequentially. All samples and standards were placed in duplicate. Chromogen and metmyoglobin were added to both samples and standards. Hydrogen peroxide was added and then the plate was incubated. The absorbances of the standards and samples were measured at 750 nm using a microplate spectrophotometer (Multiscan GO, Thermo Scientific, Finland) after incubation.
Calculations of each standard and sample were made to evaluate the assay. A standard Trolox curve was plotted with the mean absorbance of the standards. The TACs of the samples were calculated according to the formula using the linear regression of that standard curve and the average of the absorbance of samples: Antioxidant (mM) = [(Sample average absorbance) - (y-intercept)/ Slope] x Dilution
- Sperm DNA Fragmentation [ Time Frame: 3 months ]Sperm DNA Fragmentation (SDF) was analysed with TUNEL using the commercial In situ Cell Death Detection Kit. All samples were fixed with 4% paraformaldehyde (PFA). Fixed sperm samples were added onto polylysine-coated slides. Slides were kept in freshly prepared permeabilization solution on ice. For TUNEL reaction, label solution was mixed with enzyme solution, and 50 µl of the mix was dropped. Slides were incubated, afterward, they were washed three times and a mounting medium with DAPI was added. Samples were immediately examined and photographed using a fluorescent microscope. Photographs were analysed with the Image J program and at least 500 cells were evaluated from each sample. SDF was calculated as the number of sperm nuclei stained green as a percentage of the total sperm nuclei identified as blue in the same area.
- % of histone-rich spermatozoa [ Time Frame: 3 months ]Sperm pellets were washed then spread on clean slides and the smears were air dried. Dried smears were fixed with 3% glutaraldehyde and they were immersed in a 5% aniline blue solution in 4% glacial acetic acid. After staining, 200 sperm were counted at least on each slide at 1000x magnification at a light microscope. Pale blue spermatozoa that received less or no staining were considered protamine-rich, and spermatozoa partially or completely stained dark blue were evaluated as histone-rich.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 60 Years (Adult) |
Sexes Eligible for Study: | Male |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
1) Clinical diagnosis of idiopathic oligoasthenoteratozoospermia
-
Exclusion Criteria:
- Vasectomy
- Azoospermia or severe oligozoospermia
- Current use of a treatment or drug
- Cancer, heart disease or cirrhosis history
- Uncontrolled diabetes mellitus -
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT06042738
Turkey | |
Ondokuz Mayıs University | |
Samsun, Turkey |
Study Director: | Ramazan Asci | Ondokuz Mayıs University |
Documents provided by Mesut Şengül, Ondokuz Mayıs University:
Responsible Party: | Mesut Şengül, Principal investigator, Ondokuz Mayıs University |
ClinicalTrials.gov Identifier: | NCT06042738 |
Other Study ID Numbers: |
OAT2023 |
First Posted: | September 21, 2023 Key Record Dates |
Last Update Posted: | September 21, 2023 |
Last Verified: | September 2023 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
exercise antioxidant antioxidant capacity sperm DNA fragmentation protamine |
Infertility Infertility, Male Genital Diseases |
Urogenital Diseases Genital Diseases, Male Male Urogenital Diseases |